A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

July 12, 2023

Study Completion Date

July 12, 2023

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

Vaccine and vedolizumab (Entyvio)

"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."

BIOLOGICAL

Placebo vaccine and vedolizumab infusion (Entyvio)

"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."

BIOLOGICAL

Placebo vaccine and placebo infusion

"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."

Trial Locations (4)

1011

Centre d'Immunothérapie et Vaccinologie, CHUV, Lausanne

75004

Hotel Dieu, Paris

94010

Service Immunologie clinique et maladies infectieuses, Hôpital Henri Mondor, Paris

SW10 9NH

St Stephens Centre, Chelsea & Westminster Hospital, London

All Listed Sponsors
collaborator

EuroVacc Foundation

OTHER

collaborator

European AIDS Treatment Group (EATG)

UNKNOWN

collaborator

Medical Research Council

OTHER_GOV

collaborator

University College London Hospitals

OTHER

collaborator

University of Liverpool

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Henri Mondor University Hospital

OTHER

collaborator

European Georges Pompidou Hospital

OTHER

collaborator

Saint-Louis Hospital, Paris, France

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

collaborator

Chelsea and Westminster Hospital, UK

UNKNOWN

collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

"Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS"

NETWORK

collaborator

Imperial College London

OTHER

collaborator

Institut d'Investigacions Biomèdiques August Pi i Sunyer

OTHER

collaborator

European Commission

OTHER

collaborator

Swiss Government

UNKNOWN

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT04120415 - A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02) | Biotech Hunter | Biotech Hunter